trametinib (Mekinist) For treatment in combination with dabrafenib (Tafinlar) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. This is an abbreviated submission to remove the SMC restriction to first-line treatment.
trametinib (Mekinist) In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.
trametinib 0.5mg, 2mg film-coated tablets (Mekinist) In combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
dabrafenib (Tafinlar) In combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection
dabrafenib (Finlee) In combination with trametinib for the treatment of paediatric patients aged 1 year and older with low-grade glioma (LGG) with a BRAF V600 mutation who require systemic therapy. In combination with trametinib for the treatment of paediatric patients aged 1 year and older with high-grade glioma (HGG) with a BRAF V600 mutation who have received at least one prior radiation and/or chemotherapy treatment.
September 2016 decisions news release The Scottish Medicines Consortium (SMC) has today published advice accepting three new medicines for routine use in NHSScotland.
September 2024 decisions news release The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday, July 8) published advice on four medicines.
February 2019 decisions news release A medicine used to treat a rare blood cancer in children and young adults has today (Monday 11 February) been accepted by the Scottish Medicines Consortium (SMC) for use in NHSScotland.
